Sibale Mojoo Daisy, Oze Isao, Tsuge Hiroshi, Taniyama Yukari, Koyanagi Yuriko N, Yamamoto Sayaka, Hori Megumi, Nakata Kayo, Sugiyama Hiromi, Miyashiro Isao, Oki Izumi, Nishino Yoshikazu, Ito Yuri, Katanoda Kota, Shibata Akiko, Matsuda Tomohiro, Matsuo Keitaro, Ito Hidemi
Division of Cancer Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan.
Department of Cancer Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Cancer Sci. 2025 Jul;116(7):1963-1971. doi: 10.1111/cas.70068. Epub 2025 Mar 31.
While male breast cancer (MBC) remains a rare and understudied disease, comparatively little is known about its prognosis in contrast to female breast cancer (FBC). There is a paucity of large population-based studies comparing the prognosis of MBC patients to FBC patients in Japan. This study analyzed 181,540 breast cancer cases, 1058 (0.6%) males and 180,482 (99.4%) females, from 12 prefectures in Japan diagnosed between 1993 and 2011. Five- and ten-year net survival (NS) were estimated and stratified by sex, period, age, stage, and histological groups. Excess hazard ratios (EHR) were adjusted for period, age, stage, and histological group. Cochran's Q test was utilized to assess heterogeneity across these factors. The overall 5- and 10-year NS estimates for MBC patients were 90.7% (95% CI: 86.3%-93.7%) and 83.7% (95% CI: 72.2%-90.8%), respectively, while those for FBC patients were 88.3% (95% CI: 88.1%-88.5%) and 79.1% (95% CI: 78.7%-79.4%), respectively. The survival of MBC patients was comparable to that of FBC patients, with EHR of 0.88 [95% CI: 0.70-1.09] and 0.86 [95% CI: 0.69-1.07] for 5- and 10-year survival, respectively. Heterogeneity analysis revealed no significant sex-based differences in survival across these strata. This study offers a comprehensive analysis of breast cancer survival in Japanese men and women and enhances understanding of MBC prognosis relative to FBC.
虽然男性乳腺癌（MBC）仍然是一种罕见且研究不足的疾病，但与女性乳腺癌（FBC）相比，人们对其预后了解相对较少。在日本，缺乏将MBC患者与FBC患者的预后进行比较的大规模基于人群的研究。本研究分析了1993年至2011年间日本12个县诊断出的181,540例乳腺癌病例，其中男性1058例（0.6%），女性180,482例（99.4%）。估计了5年和10年净生存率（NS），并按性别、时期、年龄、分期和组织学分组进行分层。对时期、年龄、分期和组织学分组调整了超额风险比（EHR）。采用 Cochr an's Q检验评估这些因素之间的异质性。MBC患者的总体5年和10年NS估计值分别为90.7%（95%CI：86.3%-93.7%）和83.7%（95%CI：72.2%-90.8%），而FBC患者的估计值分别为88.3%（95%CI：88.1%-88.5%）和79.1%（95%CI：78.7%-79.4%）。MBC患者的生存率与FBC患者相当，5年和10年生存率的EHR分别为0.88[95%CI：0.70-1.09]和0.86[95%CI：0.69-1.07]。异质性分析显示，在这些分层中，生存方面没有显著的性别差异。本研究对日本男性和女性乳腺癌生存情况进行了全面分析，并增进了对MBC相对于FBC预后的理解。
